Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
Ziad Bakouny(Dana-Farber Cancer Institute), Srinivas R. Viswanathan(Dana-Farber Cancer Institute), Wenting Pan(Beijing University of Chemical Technology), Ronan Flippot(Institut Gustave Roussy), David F. McDermott(Beth Israel Deaconess Medical Center), Petra Ross‐Macdonald(Bristol-Myers Squibb (United States)), Maura Sticco-Ivins(Brigham and Women's Hospital), Miriam Sant’Angelo(Brigham and Women's Hospital), Mark M. Pomerantz(Dana-Farber Cancer Institute), Steven L. Chang(Brigham and Women's Hospital), Meng Xiao He(Broad Institute), Michelle S. Hirsch(Perinatal Institute), Gabrielle Bouchard(Dana-Farber Cancer Institute), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Yue Hou(Inner Mongolia Medical University), Xiao X. Wei(Dana-Farber Cancer Institute), Jackson Nyman(Dana-Farber Cancer Institute), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Giannicola Genovese(The University of Texas MD Anderson Cancer Center), Catherine J. Wu(Dana-Farber Cancer Institute), Laure Hirsch(Harvard University), Michael B. Atkins(Georgetown University), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Miriam Ficial(Barts Health NHS Trust), Lauren C. Harshman(Dana-Farber Cancer Institute), Sylvan C. Baca(Broad Institute), Thai H. Ho(Mayo Clinic in Arizona), Maxine Sun(Université de Montréal), Jacob E. Berchuck(Dana-Farber Cancer Institute), Bradley A. McGregor(Harvard University), Alice Bosma-Moody(Dana-Farber Cancer Institute), Abdallah Flaifel(Brigham and Women's Hospital), Wanling Xie(Dana-Farber Cancer Institute), Kevin Bi(Broad Institute), David A. Braun(Yale Cancer Center), Amin H. Nassar(Brigham and Women's Hospital), Sachet A. Shukla(Broad Institute), Leigh Ellis(Prostate Cancer Research), Matthew L. Freedman(Brigham and Women's Hospital), Sabrina Y. Camp(Dana-Farber Cancer Institute), Natalie I. Vokes(The University of Texas MD Anderson Cancer Center), Megan Wind‐Rotolo(Bristol-Myers Squibb (United States)), Jihye Park(Broad Institute), Xīn Gào(Massachusetts General Hospital), Shaan Dudani(William Osler Health System), W. Marston Linehan(National Cancer Institute), Juliet Forman(Broad Institute), Stephen Tang(Columbia University), Daniel Y.C. Heng(University of Calgary), Sarah Abou Alaiwi(Yale New Haven Hospital)
Cited by 167
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k